ACROBiosystems/人ASGR1/ASGPR1蛋白，Fc标签/1mg/AS1
商品编号：
AS1
品牌：
ACROBiosystems
市场价：
¥0.00
美元价：
0.00
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
This product is still under development. Please contact us if you have interest in this product. We will accelerate the development process accordingly and reserve this product for you as request.
- SynonymASGP-R 1, ASGPR 1, C-type lectin domain family 4 member H1, Hepatic lectin H1, HL-1
- SourceHuman ASGR1, Fc Tag (AS1-H5253) is expressed from human 293 cells (HEK293). It contains AA Gln 62 - Leu 291 (Accession # P07306-1).Predicted N-terminus: Gln 62
- Molecular Characterization
This protein carries a human IgG1 Fc tag at the N-terminus.
The protein has a calculated MW of 52.8 kDa.
- Endotoxin
- Formulation
Please contact us for detailed information.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.
- BackgroundASGPR, a transmembrane C-type lectin, recognizes a wide variety of ligands that contain either terminal galactose (Gal) or N-acetylgalactosamine (GalNAc) residues and has been identified as a highly selective receptor on hepatocytes. The ASGR is composed of both a major (ASGR1) and minor subunit (ASGR2). ASGR1 has been shown to be efficiently targeted to the plasma membrane and to undergo constitutive endocytosis and recycling and found mainly expressed in the human liver.
- References
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
品牌介绍
ACROBiosystems 是一个具有全球范围影响力的生物技术领导品牌，其运营包括了位于北美、 欧洲和亚洲的数家公司， 主要为生命科学研究、生物制药与疫病诊断等行业提供产品、技术服务和临床应用等解决方案，同时致力于在蛋白组学、药物发现和细胞治疗等领域推广面向工业化和临床转化的技术和产品。ACROBiosystems 的业务遍及全球50多个国家和地区，并通过在北美、亚洲、欧洲等世界范围的不同时区设立分支机构以服务于当地客户与经销商。
